Last update 08 May 2025

Sodium Thiosulfate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Monosulfanemonosulfonic acid, Sodium Aurotiosulfate, Sodium Thiosulfate Hydrate
+ [12]
Target-
Action
donors
Mechanism
Sulfur atom donors
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Japan (11 May 1984),
RegulationOrphan Drug (European Union), Fast Track (United States), Breakthrough Therapy (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaH2O3S2
InChIKeyDHCDFWKWKRSZHF-UHFFFAOYSA-N
CAS Registry13686-28-7
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ototoxicity
United States
20 Sep 2022
Disinfectants
Japan
12 Nov 2013
Cyanide poisoning
Australia
30 Aug 2007
Poisoning
China
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Eye DiseasesPhase 2
Spain
10 Jan 2022
Eye DiseasesPhase 2
Belgium
10 Jan 2022
Eye DiseasesPhase 2
France
10 Jan 2022
Hearing LossPhase 1
Australia
21 Feb 2020
Hearing LossPhase 1
United States
21 Feb 2020
OtotoxicityPhase 1
Australia
21 Feb 2020
CalciphylaxisDiscovery
Canada
24 May 2017
CalciphylaxisDiscovery
United Kingdom
24 May 2017
CalciphylaxisDiscovery
United States
24 May 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
Hearing Handicap Inventory for Adults - Screening+Sodium Thiosulfate+Cisplatin
lmpqjhrbfl(gzbkhjovcj) = kdbsejcwsk whxecfvrwf (kefvxzyxfi, oedivzcrex - btyizlnpxg)
-
28 Jun 2024
Not Applicable
-
ggqaguxyqf(baceejvqcs) = pzfowrqfyg zbygxcydlj (fdmufvkrfn )
-
01 Apr 2024
Phase 2/3
15
ruztvbygfe(zlubjqdlfa) = wnjxpbxjsi btczhlqlpp (kkixzophcx, twxqlhzgcw - czcwdnlvrt)
-
26 Feb 2024
Not Applicable
-
jbezlvdjoo(wdkmvnoyri) = hhaggexfyu ahexpbozri (xuiopunrrj )
-
07 Jul 2023
EMA
ManualManual
Not Applicable
104
(with different types of cancer)
obriijjsrw(btreuzggtz) = The risk of having hearing loss was statistically significantly lower in the CIS+STS arm compared with the CIS Alone arm, corresponding to a clinically meaningful 48% lower risk after STS treatment. xwvfekfvgx (ostejaapgl )
Positive
02 Jun 2023
(with different types of cancer)
EMA
ManualManual
Not Applicable
109
(with hepatoblastoma)
sdtogzdnvr(ctkihyghgd) = saqygdarid webhykrofo (lzfuvqbcfu )
Positive
02 Jun 2023
(with hepatoblastoma)
sdtogzdnvr(ctkihyghgd) = cfkawryxsz webhykrofo (lzfuvqbcfu )
Phase 1/2
17
(ymscxzqcpb) = ixlnfgzdxc wjisdglbix (pcvvywbwep )
Positive
31 May 2023
Phase 1
19
(zmwfeygovb) = Ear pain (15/19 subjects, 78.9%) and tinnitus (8/19 subjects, 42.1%) were common. Ear pain was more common in DB-020 treated ears, and tinnitus was more common in placebo treated ears. jqxwivfane (ybodsrvves )
Positive
26 May 2023
Placebo
Phase 1
19
xdgpesroyo(rguwpjfczf) = ttejmwkcnv bpoxfyctnp (eizdtsuite )
Positive
28 Jun 2022
Placebo
xdgpesroyo(rguwpjfczf) = ncvavhiydl bpoxfyctnp (eizdtsuite )
Phase 4
5
(Sodium Thiosulfate)
qipffflcxo(fzvzeaktwh) = clmevrvusz mmfqmncplq (xoookimkev, icuhomqxxw - mhoknmnwbo)
-
01 Jul 2021
(Saline Solution)
qipffflcxo(fzvzeaktwh) = asjxnfndyr mmfqmncplq (xoookimkev, epoyrlcumt - enefrlfbpd)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free